CEUS or Contrast enhanced Ultrasound
ApprovedSmall molecule
CEUS or Contrast enhanced Ultrasound is one of 61 small molecule programs targeting Hematoma. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1CEUS or Contrast enhanced Ultrasound
TTurku University Hospital
Approved
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cetrotide
EMD SeronoPreclinical
Spravato
WWim Janssens
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTurku University Hospital